.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,585,115

« Back to Dashboard

Claims for Patent: 5,585,115

Title: Pharmaceutical excipient having improved compressability
Abstract:A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.
Inventor(s): Sherwood; Bob E. (Amenia, NY), Hunter; Edward A. (Glenham, NY), Staniforth; John H. (Bath, GB2)
Assignee: Edward H. Mendell Co., Inc. (Patterson, NY)
Application Number:08/370,576
Patent Claims: 1. An excipient composition comprising a particulate agglomerate of microcrystalline cellulose coprocessed with from about 0.1% to about 20% by weight silicon dioxide, the microcrystalline cellulose and silicon dioxide being in intimate association with each other and said silicon dioxide being integrated with or partially coating said microcrystalline cellulose, said silicon dioxide portion of said agglomerate being derived from a silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m.

2. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from a silicon dioxide having an average primary particle size from about 5 nm to about 40 .mu.m.

3. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from colloidal silicon dioxide.

4. The composition of claim 1, wherein said silicon dioxide is included in amount from about 0.1% to about 20% by weight, based on the weight of microcrystalline cellulose.

5. The composition of claim 1, wherein said silicon dioxide is from about 0.5% to about 10% by weight, based on the weight of said microcrystalline cellulose.

6. The composition of claim 1, wherein said silicon dioxide is included in an amount of from about 1.25% to about 5%, based on the weight of said microcrystalline cellulose.

7. The composition of claim 1, wherein said excipient particles have an average particle size of from about 10 .mu.m to about 1,000 .mu.m.

8. The composition of claim 1, wherein said excipient particles have an average particle size of from about 10 .mu.m to about 500 .mu.m.

9. The composition of claim 1, wherein said excipient particles have an average particle size of from about 30 .mu.m to about 250 .mu.m.

10. The composition of claim 1, wherein said excipient particles have a moisture content from about 0.5% to about 15%.

11. The composition of claim 1, wherein said excipient particles further comprise a member of the group consisting of non-silicon metal oxides, starches, starch derivatives, surfactants, polyalkylene oxides, celluloses, cellulose ethers, cellulose esters and mixtures thereof.

12. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from a silicon dioxide having a surface area from about 10 m.sup.2 /g to about 500 m.sup.2 /g.

13. The composition of claim 1, wherein said silicon dioxide portion of said agglomerate is derived from a silicon dioxide having a surface area from about 175 m.sup.2 /g to about 350 m.sup.2 /g.

14. The composition of claim 1, wherein said excipient has a bulk density from about 0.2 g/ml to about 0.6 g/ml.

15. The composition of claim 3, wherein said excipient has a bulk density from about 0.35 g/ml to about 0.55 g/ml.

16. An excipient composition, comprising from about 1% to about 99% of an excipient comprising a particulate agglomerate of microcrystalline cellulose coprocessed with from about 0.1% to about 20% silicon dioxide by weight of said microcrystalline cellulose, the microcrystalline cellulose and silicon dioxide being in intimate association with each other and said silicon dioxide being integrated with or partially coating said microcrystalline cellulose, and the silicon dioxide portion of said agglomerate being derived from a silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m, and from about 99% to about 1% of an active ingredient.

17. The composition of claim 16, wherein the silicon dioxide portion of said agglomerate is derived from a silicon dioxide having an average primary particle size from about 5 nm to about 40 .mu.m.

18. The composition of claim 16, wherein the silicon dioxide portion of said agglomerate is derived from colloidal silicon dioxide.

19. The composition of claim 16 which has been wet granulated.

20. The composition of claim 18, which has been wet granulated.

21. The composition of claim 16, which has been incorporated into a solid form.

22. An excipient composition, comprising a particulate excipient of microcrystalline cellulose integrated with from about 0.1% to about 20% silicon dioxide by weight of said microcrystalline cellulose, said silicon dioxide coprocessed with and partially coating said microcrystalline cellulose and silicon dioxide portion of said excipient being derived from silicon dioxide having a surface area from about 10 m.sup.2 /g to about 500 m.sup.2 /g.

23. The composition of claim 22, wherein said silicon dioxide portion of said excipient is derived from silicon dioxide having a surface area from about 175 m.sup.2 /g to about 350 m.sup.2 /g.

24. The composition of claim 22, wherein said silicon dioxide portion of said excipient is derived from colloidal silicon dioxide.

25. The composition of claim 1, which has been wet granulated.

26. The composition of claim 1, which has been incorporated into a solid form.

27. The composition of claim 1, which has been wet granulated with an active agent.

28. The composition of claim 26, wherein said composition has been wet granulated with, wherein said excipient particles further comprise a member of the group consisting of non-silicon metal oxides, starches, starch derivatives, surfactants, polyalkylene oxides, celluloses, cellulose ethers, cellulose esters and mixtures thereof.

29. The composition of claim 22, which has been wet granulated.

30. The composition of claim 22, which has been wet granulated with an active agent.

31. The composition of claim 22, wherein said excipient particles further comprise member of the group consisting of non-silicon metal oxides, starches, starch derivatives, surfactants, polyalkylene oxides, celluloses, cellulose ethers, cellulose esters and mixtures thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc